Login
DexCom NASDAQ: DXCM
DexCom, Inc. is a company that develops, manufactures and distributes continuous glucose monitoring systems for diabetes management
| Name | DexCom |
| Ticker | DXCM |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Diabetes |
|
Price
52W Low/High |
391.10
291.69 / 451.79 |
| Momentum | Neutral |
| Market cap | 38 B |
| 1Y Total Return |
34.08%
Below Average |
| 1Y Volatility |
46.14%
Average Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
DexCom, Inc. is a company that develops, manufactures and distributes continuous glucose monitoring systems for diabetes management
Details
| Ticker | DXCM |
| Name | DexCom |
| ISIN | US2521311074 |
| CUSIP | 252131107 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Diabetes |
| Country | USA |
| Currency | U.S. Dollar |
Share as of 4/14/21
| Close Price | 391.10 |
| 52W Low/High | 291.69 / 451.79 |
| Market cap | 38 B |
| 1Y Total Return |
34.08%
Below Average |
| 1Y Volatility |
46.14%
Average Risk |
| Beta | 1.90 |
| PE (trailing) |
77.29
High |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | 25.6% |
| Cash from Op. / Cur. Liabilities | 0.77 |
| Diluted Earnings / Share | 5.06 |
| ROE | 36.4% |
| ROIC | 49.8% |
| Price / Revenue | 19.8 |
| Price / Book | 20.9 |
| Price / CF | 80.2 |
| Current Ratio | 5.6 |
| Cur.Liabilities / Tot.Liabilities | 0.2 |
| Financial Leverage | 0.98 |
| in Mils USD |
rolling-year up to December
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
1,927
|
1,476
|
1,032
|
719
|
573
|
402
|
|
| Gross Profit |
1,280
|
932
|
664
|
492
|
378
|
278
|
|
| R&D |
360
|
274
|
200
|
185
|
156
|
138
|
|
| EBITDA |
377
|
213
|
-75
|
-20
|
-49
|
-46
|
|
| Operating Income |
300
|
142
|
-186
|
-43
|
-64
|
-57
|
|
| Net Income exc. Extra |
494
|
101
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
98
|
92
|
88
|
86
|
84
|
80
|
|
| EPS exc. Extra |
5.06
|
1.10
|
-1.44
|
-0.58
|
-0.78
|
-0.72
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
4,291
|
2,395
|
1,916
|
904
|
403
|
292
|
|
| Cash, Eq & Invt ShortTerm |
2,708
|
1,533
|
1,386
|
549
|
124
|
115
|
|
| Total Current Assets |
3,425
|
1,969
|
1,700
|
745
|
280
|
231
|
|
| Total Non-Current Assets |
866
|
426
|
217
|
159
|
123
|
61
|
|
| Intangibles |
19
|
19
|
19
|
12
|
11
|
6
|
|
| Total Liabilities |
2,464
|
1,512
|
1,253
|
485
|
119
|
71
|
|
| Total Current Liabilities |
614
|
360
|
222
|
139
|
102
|
67
|
|
| Long Term Debt |
1,850
|
1,152
|
1,030
|
346
|
17
|
4
|
|
| Shareholder equity |
1,827
|
883
|
663
|
419
|
284
|
221
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
476
|
315
|
123
|
92
|
56
|
49
|
|
| Depreciation |
67
|
49
|
29
|
16
|
15
|
11
|
|
| Cash from Investing |
-1,018
|
-1,015
|
-140
|
-144
|
-56
|
-52
|
|
| Capex |
199
|
180
|
67
|
66
|
56
|
33
|
|
| Cash from Financing |
912
|
11
|
710
|
399
|
8
|
17
|
|
| Stock Issued |
15
|
12
|
95
|
10
|
10
|
19
|
|
| Debt (LT) Issued |
906
|
0
|
618
|
389
|
0
|
-2
|
|
| Free Cash Flow |
883
|
-23
|
-240
|
-112
|
-142
|
-133
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
25.6%
|
6.8%
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
158.8%
|
221.0%
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
5.6
|
5.5
|
7.6
|
5.4
|
2.7
|
3.5
|
|
| Financial Leverage D/E |
0.98
|
1.30
|
1.52
|
0.78
|
0.00
|
0.01
|
|
| Return on Capital Avg |
49.8%
|
15.7%
|
-23.9%
|
-13.9%
|
-37.5%
|
-54.6%
|
|
| Return on Shareholder Equity |
36.4%
|
13.1%
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available